8-K filed Aug 5, 2026 at 08:02 ET
UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4M in revenue (73% QoQ growth). EPS of -$0.28 was a 5.7% miss vs consensus -$0.27. The company raised FY2026 operating expense guidance to $260M-$270M to accelerate ZUSDURI commercialization and pipeline investment. ZUSDURI's accelerating launch trajectory and a new patent allowance extending protection to 2044 are strong positives, but the EPS miss and rising spend temper the outlook.